Article

Did pay for performance pay off in England?

A pay-for-performance (P4P) scheme based on meeting targets for the quality of clinical care introduced to family practice in England in 2004 accelerated improvements in quality for 2 of 3 chronic conditions in the short term. However, the initial acceleration in improvement was not sustained.

A pay-for-performance (P4P) scheme based on meeting targets for the quality of clinical care introduced to family practice in England in 2004 accelerated improvements in quality for 2 of 3 chronic conditions in the short term. However, the initial acceleration in improvement was not sustained.

Campbell and coworkers analyzed the quality of health care in a group of 42 practices before and after a P4P system was started. They focused on care given to patients who had asthma, diabetes mellitus (DM), or heart disease and asked patients how they felt about access to and continuity of care.

The quality of care for asthma and DM, but not heart disease, increased during the first 2 years of the new system-a continuation of a trend that started before P4P was introduced. After this initial uptick, however, the rate of improvement slowed for all 3 conditions. Across all conditions, quality scores for care that was linked to incentives were higher than scores for care not linked to incentives.

The authors noted that patients’ perceptions of continuity of care declined right after the P4P scheme was introduced, but their opinions about access to care and interpersonal aspects of care remained unchanged.

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.